Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
397.5 USD -0.06% Intraday chart for Vertex Pharmaceuticals Incorporated +0.81% -2.31%
Apr. 26 Vertex Pharmaceuticals Gets European Commission Approval for Cystic Fibrosis Treatment for Infants MT
Apr. 26 Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 56,303 61,457 55,834 74,127 104,849 102,732 - -
Enterprise Value (EV) 1 52,495 54,798 48,309 63,349 93,630 85,818 81,450 77,391
P/E ratio 48.5 x 23 x 24.4 x 22.5 x 29.3 x 26.7 x 23.2 x 20.9 x
Yield - - - - - - - -
Capitalization / Revenue 13.5 x 9.9 x 7.37 x 8.3 x 10.6 x 9.58 x 8.75 x 7.96 x
EV / Revenue 12.6 x 8.83 x 6.38 x 7.09 x 9.49 x 8 x 6.94 x 6 x
EV / EBITDA 27.7 x 15.2 x 10.8 x 12.8 x 20.6 x 16.2 x 14.1 x 12.3 x
EV / FCF 35.1 x 18.3 x 20.1 x 16.1 x 28.1 x 19.8 x 17.5 x 14.4 x
FCF Yield 2.85% 5.46% 4.99% 6.2% 3.56% 5.06% 5.7% 6.96%
Price to Book 9.38 x 7.07 x 5.53 x 5.33 x 5.96 x 5.01 x 4.32 x 4.04 x
Nbr of stocks (in thousands) 257,150 260,038 254,252 256,691 257,683 258,459 - -
Reference price 2 219.0 236.3 219.6 288.8 406.9 397.5 397.5 397.5
Announcement Date 1/30/20 2/1/21 1/26/22 2/7/23 2/5/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 4,163 6,206 7,574 8,931 9,869 10,723 11,744 12,906
EBITDA 1 1,893 3,601 4,470 4,941 4,556 5,298 5,774 6,271
EBIT 1 1,786 3,491 4,344 4,793 4,375 4,971 5,453 6,057
Operating Margin 42.9% 56.25% 57.35% 53.67% 44.33% 46.35% 46.43% 46.93%
Earnings before Tax (EBT) 1 1,395 3,117 2,730 4,232 4,380 4,838 5,608 6,423
Net income 1 1,177 2,712 2,342 3,322 3,620 3,857 4,445 5,097
Net margin 28.27% 43.7% 30.92% 37.2% 36.68% 35.97% 37.85% 39.49%
EPS 2 4.510 10.29 9.010 12.82 13.89 14.90 17.11 19.01
Free Cash Flow 1 1,494 2,994 2,408 3,925 3,337 4,344 4,642 5,387
FCF margin 35.89% 48.24% 31.8% 43.95% 33.81% 40.51% 39.53% 41.74%
FCF Conversion (EBITDA) 78.92% 83.15% 53.89% 79.44% 73.24% 82% 80.4% 85.9%
FCF Conversion (Net income) 126.94% 110.4% 102.84% 118.16% 92.19% 112.62% 104.43% 105.69%
Dividend per Share 2 - - - - - - - -
Announcement Date 1/30/20 2/1/21 1/26/22 2/7/23 2/5/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 1,984 2,073 2,098 2,196 2,334 2,303 2,375 2,493 2,484 2,518 2,579 2,652 2,709 2,778 2,691
EBITDA 1 - - - - - - - - 1,215 1,210 1,256 1,277 1,284 1,250 -
EBIT 1 1,188 1,124 1,166 1,187 1,289 1,150 902.3 1,148 1,173 1,151 1,201 1,224 1,240 1,270 1,326
Operating Margin 59.89% 54.23% 55.61% 54.05% 55.24% 49.95% 37.99% 46.04% 47.24% 45.73% 46.57% 46.15% 45.76% 45.73% 49.3%
Earnings before Tax (EBT) 1 1,083 870.9 954.8 1,024 1,176 1,077 891.5 1,162 1,179 1,148 1,185 1,203 1,223 1,229 1,286
Net income 1 851.9 770.1 762.1 810.5 930.5 818.9 699.8 915.7 1,035 968.8 946.6 960 970.7 960.6 1,016
Net margin 42.94% 37.16% 36.33% 36.9% 39.86% 35.56% 29.47% 36.73% 41.69% 38.48% 36.7% 36.2% 35.83% 34.58% 37.76%
EPS 2 3.280 3.000 2.960 3.130 3.590 3.150 2.690 3.520 3.970 3.710 3.680 3.720 3.774 3.801 3.850
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/2/21 1/26/22 5/5/22 8/4/22 10/27/22 2/7/23 5/1/23 8/1/23 11/6/23 2/5/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 3,808 6,659 7,525 10,779 11,218 16,914 21,283 25,342
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 1,494 2,994 2,409 3,925 3,337 4,344 4,642 5,387
ROE (net income / shareholders' equity) 22.4% 36.7% 36% 32.1% 23% 22.7% 21.1% 22.7%
ROA (Net income/ Total Assets) 16.2% 27% 18.8% 21% 17.7% 15.1% 13.6% 12.9%
Assets 1 7,282 10,035 12,433 15,792 20,441 25,503 32,795 39,453
Book Value Per Share 2 23.30 33.40 39.70 54.10 68.20 79.30 92.00 98.50
Cash Flow per Share 2 6.020 12.40 10.20 15.90 13.60 19.30 19.90 20.30
Capex 1 75.5 260 235 205 200 216 224 238
Capex / Sales 1.81% 4.19% 3.1% 2.29% 2.03% 2.01% 1.91% 1.85%
Announcement Date 1/30/20 2/1/21 1/26/22 2/7/23 2/5/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
397.5 USD
Average target price
459.7 USD
Spread / Average Target
+15.66%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.71% 8.24B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VRTX Stock
  4. Financials Vertex Pharmaceuticals Incorporated